• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis. A novel I221 L substitution in neuraminidase confers high level resistance to oseltamivir in influenza B viruses

Giuseppe

Emeritus
[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]


A novel I221 L substitution in neuraminidase confers high level resistance to oseltamivir in influenza B viruses

Vanessa Escuret 1,2,*, Patrick J. Collins 5,*, Jean-S?bastien Casalegno 1,2,*, Sebastien G. Vachieri 5,6,*, Nicholas Cattle 4, Olivier Ferraris 2, Murielle Sabatier 2, Emilie Frobert 1,2, Val?rie Caro 7, John J. Skehel 5, Steve Gamblin 6, Fr?d?ric Valla 3, Martine Valette 1, Mich?le Ottmann 2, John W. McCauley 4, Rodney S. Daniels 4 and Bruno Lina 1,2

Author Affiliations: <SUP>1</SUP>Hospices Civils de Lyon, Groupement Hospitalier Est, Laboratoire de Virologie et Centre National de R?f?rence virus influenzae, F-69677, Bron, France <SUP>2</SUP>Universit? de Lyon, Universit? Claude Bernard Lyon 1, Facult? de M?decine Lyon Est, EA 4610, F-69372, Lyon, France <SUP>3</SUP>Hospices Civils de Lyon, Groupement Hospitalier Est, H?pital Femme M?re Enfant, Service de R?animation P?diatrique, , F-69677, Bron, France <SUP>4</SUP>WHO Collaborating Centre for Reference and Research on Influenza, Division of Virology, Medical Research Council National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom <SUP>5</SUP>Division of Virology, Medical Research Council National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom <SUP>6</SUP>Division of Molecular Structure, Medical Research Council National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom <SUP>7</SUP>Institut Pasteur, Genotyping of Pathogens and Public Health Platform, 28 rue du Docteur Roux , 75724 Paris Cedex 15, France

Corresponding author: Dr Vanessa Escuret or Pr. Bruno Lina, Laboratoire de Virologie - B?t A3, 59 Boulevard Pinel, F-69677 Bron Cedex, France, T?l?phone : 04 72 12 96 17, Fax : 04 72 12 95 00, Email : vanessa.escuret@chu-lyon.fr, bruno.lina@chu-lyon.fr

* These authors contributed equally to the work


Abstract

Introduction.

Influenza B viruses with a novel I221 L substitution in neuraminidase (NA) conferring high level resistance to oseltamivir were isolated from an immunocompromised patient after prolonged oseltamivir treatment.


Methods.

Enzymatic characterization of the NAs (Km, Ki) and the in vitro fitness of viruses carrying wild-type (wt) or mutated (I221 L) NA genes were evaluated. Proportions of wt and mutated NA genes were directly quantified in the patient samples. Structural characterizations by X-ray crystallography of a wt and I221 L variant NA were performed.


Results.

The Km and Ki revealed that the I221 L variant NA had approximately 84 and 51 times lower affinity for oseltamivir carboxylate and zanamivir respectively compared to wt NA.

Viruses with a wt or I221 L variant NA had similar growth kinetics in MDCK cells and five passages in MDCK cells revealed no reversion of the I221 L substitution. The crystal structure of the I221 L NA and oseltamivir complex showed that the leucine side-chain protrudes into the hydrophobic pocket of the active site that accommodates the pentyloxy substituent of oseltamivir.


Conclusions.

Enzyme kinetic and NA structural analyses provide an explanation for the high resistance to oseltamivir, while retaining good virus fitness of viruses carrying I221 L variant NA.


Received February 10, 2014. Revision received April 17, 2014. Accepted April 17, 2014.

? The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.


-
-------
 
Back
Top Bottom